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SeminarsFrom two anticoagulants and one anti-aggregant, the number of currently available drugs has recently
increased several-fold, leaving clinicians with the problem of choosing the optimal agent. Individualized
preoperative assessment of bleeding risk based on bleeding history and testing limited to high-risk patients
is an emerging concept. Based on the identiﬁcation of risk factors for venous thromboembolism (VTE),
pharmacologic and non-pharmacologic strategies for perioperative VTE prophylaxis have had a major
impact on patient outcome. For patients undergoing surgery who are treated with anticoagulants and
anti-aggregants, “bridging” strategies have been proposed. Bleeding management strategies have shifted
focus from replacing lost blood volume to new approaches aimed at preventing blood loss, reducing the
potential complications of blood loss, and preventing the transfusion of blood products. For some areas of
perioperative thrombosis and hemostasis management, randomized controlled trial (RCT) data are
emerging, but the database remains insufﬁcient to date. Clearly, more RCTs need to be published for
perioperative thrombosis and hemostasis management to become an evidence-based approach.
Semin Hematol 50:79–87. C 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.EDITOR'S NOTE
This is a “special” article celebrating the 50th anniversary
of Seminars in Hematology. Dr Serena Valsami from the
University of Athens, Greece and Dr Lars Asmis from the
University of Zurich, Switzerland, in a comprehensive review,
discuss management of perioperative thrombosis and hemo-
stasis. Identiﬁcation of risk factors and development of new
drugs greatly changed the incidence and evolution of
thrombotic and hemorrhagic complications, which was the
“nightmare” of patients and surgeons. The value of prospec-
tive randomized clinical trials in the elaboration of guidelines
in this matter is clearly seen in this well-written review.
INTRODUCTION
The management of patients undergoing a surgical
procedure has changed considerably over the past 50 years.blished by Elsevier Inc.
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Open access under CC BY-NC-ND license.This brief review will focus on some of the key changes in
the ﬁeld of perioperative thrombosis and hemostasis
management, discussing where the ﬁeld set out 50 years
ago, what changed since then, and where it is today.DEVELOPMENTS IN ANTICOAGULANTS
In the 1960s when Seminars in Hematology was
founded, the mainstay of anticoagulant therapy was
unfractionated heparin and vitamin K antagonists (VKAs).
In the ﬁrst half of the past 50 years much was learned
about the mechanism of action of these drugs, while in the
second half new molecules were added to the palette of
available anticoagulants.
Heparin was discovered by McLean in 1916 and was
isolated from dog livers (Greek for liver: hepar), which
gave the anticoagulant its name.1 VKAs were determined
to be a cause of a hemorrhagic disease in cows by Charles
Link. They were ﬁrst used as a potent poison for rodents.
It was not until the 1950s that the drug found its way into
clinical medicine.
In 1968, Abildgaard showed that the protein antith-
rombin was necessary for heparin’s anticoagulant action,
illustrating that the heparins were indirect anticoagulants.2
Warfarin inhibits coagulation by disturbing hepatic post-
translational modiﬁcation of coagulation factors (FII,
FVII, FIX, and FX) and inhibitors (proteins C and S).
Without the postranslationally added carboxyl groups,79
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and thus are dysfunctional. Because neither anticoagulant
family, the heparins and the vitamin K antagonists (VKAs),
binds directly to the active center of coagulation factors,
they are called indirect anticoagulants. One of the problems
with unfractionated heparins (5–30 kd; mean molecular
weight [MW], 15 kd) was that they did not have a ﬁxed
dose-response relationship. This was in part due to unspe-
ciﬁc binding of these long, negatively charged molecules to
many other targets, including acute-phase reactants, plate-
lets, and endothelial cells. Monitoring was necessary to
titrate the correct dose in each patient.
Fractionation or isolation of smaller heparin fragments
provided a solution to the dose-response problem. By
generating mixtures of small fragments of heparin (2–9 kd;
mean MW, 4–6 kd) the product obtained a ﬁxed dose-
response relationship and weight-based dosing was possi-
ble. Monitoring was no longer obligatory. The exact
mechanism of heparin action was elucidated in the late
1970s by the ﬁnding that heparins bind to antithrombin
through a unique pentasaccharide motif. Only molecules
that harbor this pentasaccharide sequence are biologically
active in coagulation inhibition. The exact sequence was
identiﬁed by Choay in 1985.3 This paved the way to the
generation of a synthetic pentasaccharide, fondaparinux.
Even though hirudin, derived from the medicinal leach
(hirudo medicinalis), was one of the ﬁrst anticoagulants to
be described in the late 19th centrury, it could not be used
for clinical anticoagulation in view of the narrow ther-
apeutic window and lack of adequate monitoring tests.4
Hirudin found an application as an alternative antico-
agulant in case of heparin-induced thrombocytopenia
(HIT).5 HIT is an antibody-mediated adverse drug effect
with antibodies directed against complexes of heparin and
platelet factor 4 that was described in 1958 by Weismann
and Tobin.6 Hirudin derivatives, such as lepirudin and
bivalirudin, still are used for this indication. These anti-
coagulants are characterized by directly attacking the active
sites of thrombin or FIIa. The molecule binds directly to
the so-called serine protease domain, thereby inhibiting
the activated coagulation factor. All of these direct anti-
coagulants had the problem that they could only be used
parenterally. The search for new oral agents began.
The ﬁrst new oral direct anticoagulant that made it into
clinical practice was ximelagatran, a direct thrombin
inhibitor. In view of its hepatotoxicity, the drug was
withdrawn again from the market in 2006. The next direct
thrombin inhibitor to be approved by a large national
health agency was dabigatran, with initial indication for
the prevention of venous thromboembolism (VTE) in hip
or knee replacement surgery in 2008 in Canada and
Europe and later for prevention of stroke in atrial
ﬁbrillation by the US Food and Drug Administration
(FDA) in 2010. Argatroban is another direct thrombin
inhibitor that has gained market approval.
Another class of direct oral anticoagulants, the direct
inhibitors of FXa, soon followed. Rivaroxaban gainedapproval by Canadian and European health authorities for
VTE prevention in hip and knee replacement in 2008. In
2011 it became FDA-approved for the treatment of deep
vein thrombosis (DVT) and stroke prevention in atrial
ﬁbrillation. The FDA approved the treatment of DVT and
pulmonary embolism in 2012. Apixaban, edoxaban, and
other related compounds have or are in the process of
obtaining health agency approval for various indications.DEVELOPMENTS IN ANTIPLATELET AGENTS
In the 1960s aspirin was the main antiplatelet agent in
clinical use. Aspirin (acetylsalicylic acid) was ﬁrst produced
by Felix Bayer in 1897 and almost immediately found
wide application as an anti-inﬂammatory and antipyretic
drug.7 Almost 50 years later, in 1938, its impact on
impairing hemostasis was noted in patients treated with
aspirin who experienced prolonged bleeding after tonsil-
lectomy. In the 1950s, aspirin was then prescribed to
prevent coronary and cerebral thrombosis in high-risk
patients, with remarkable results.8 The effect of aspirin on
the hemostatic properties of human platelets, by inhibition
of adenosine diphosphate (ADP)-induced secondary pla-
telet aggregation, was shown by different groups during
the 1960s.9,10 Shortly after that, aspirin’s full mechanism
of action through cyclooxygenase inhibition was eluci-
dated.11,12 In the 1980s, aspirin received approval by the
FDA for the secondary prevention of arterial vascular
disease and in the same time period, the ISIS-2 trial
proved its efﬁcacy in treating myocardial infraction.
Currently, aspirin remains an established part of the
treatment and secondary prevention of arterial throm-
boembolism.13 However, there are issues regarding aspirin
that remain unresolved, including the use of aspirin for
primary prevention of atherovascular disease and the
clinical relevance of suboptimal platelet response to aspirin
or aspirin resistance.14,15
In 1974 a P2Y12 antagonist, a thienopyridine derivate
later named ticlopidine, was ﬁrst discovered. Ticlopidine
gained FDA approval in 1991. Its antithrombotic action
was found to be equally effective to that of aspirin for the
treatment of patients with atherovascular disease. Unfortu-
nately, ticlopidine was associated with serious side effects,
including bone marrow toxicity and thrombotic thrombo-
cytopenic purpura. This drug was soon replaced by a
second thienopyridine, clopidogrel.16,17 In 1996, clopi-
dogrel proved its clinical efﬁcacy versus aspirin in patients
at risk for ischemic events and was approved for clinical
use 2 years later. Clopidogrel is a prodrug that requires
oxidation by two-stage hepatic cytochrome (CY) P450 to
generate its active metabolites, which inhibit platelets for
the lifespan. This explains the delayed onset of platelet
inhibition (4–8 hours) by clopidogrel. The variability of
the antiplatelet drug effect and the clinical efﬁcacy of
clopidogrel therapy were associated with the cytochrome
P450 2C19 (CYP2C19) genotype.18,19 The third thieno-
pyridine approved in 2011 was prasugrel, which requires
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2–4 hours. Compared to clopidogrel, prasugrel has a
greater platelet-inhibiting effect, which is not inﬂuenced
by polymorphisms of cytochrome CYP2C19 but is
associated with a higher incidence of bleeding.20 Ticagre-
lor, unlike the thienopyridines, is a direct and reversible
P2Y12 antagonist that does not require activation by liver
enzymes. Ticagrelor was found to be effective in patients
with clopidogrel resistance. However, it was associated
with side effects such as bleeding, ventricular arrhythmias,
and dyspnea.21,22 Abciximab, tiroﬁban, and eptiﬁbatide
are parenteral antiplatelet drugs acting through glycopro-
tein (GP)IIb/IIa inhibition. All three GPIIb/IIIa antago-
nists are active in preventing ischemic events complicating
percutaneous coronary interventions and in the treatment
of acute coronary syndromes.23PREOPERATIVE ASSESSMENT OF BLEEDING
RISK
In the 1960s and 1970s, preoperative coagulation
testing was the rule. Beck described a preoperative screen-
ing program for the prevention of unexpected hemorrhage
in surgical patients. From this prospective study, he
concluded that a detailed history, the prothrombin time,
and determination of platelet count “were suitable for the
speciﬁc detection of bleeding tendencies.”24 However, a
few years later Eika et al showed a complete lack of
correlation between results of preoperative screening tests
(activated partial thromboplastin time [aPTT], prothrom-
bin time, platelet count, and bleeding time) and perioper-
ative blood loss.25 Larger prospective trials followed in the
1980s. Rohrer et al compared two patient groups of 514
“screening tests” and 605 “indicated tests” (based on
bleeding history). They too concluded that preoperative
screening for coagulopathies not suspected on the basis of
detailed clinical information are unnecessary and should
not be done.26 MacPherson et al published data on 111
asymptomatic patients in whom the four above-mentioned
tests were performed and in 1,872 patients in whom
unexpectedly large perioperative transfusions were
reported. The authors concluded that in the absence of a
positive bleeding history, preoperative screening would
appear unnecessary.27 In the mid 1990s, Houry et al
performed a prospective multicenter study evaluating the
four tests in 3,242 patients. Four groups were distin-
guished according to presence or absence of positive
bleeding history and normal or pathologic perioperative
screening tests.28 Postoperatively all four groups had
similar bleeding risks. The authors concluded that peri-
operative screening should not be performed routinely.
Towards the end of the 1990s further studies showed that
preoperative bleeding time lacked clinical beneﬁt and that
preoperative von Willebrand testing provided a low yield
and limited ability to predict bleeding.29,30 A meta-
analysis by Eckman et al conﬁrmed the lack of sensitivity
or speciﬁcity for such preoperative testing strategies.31A desirable preoperative screening strategy should
primarily be sensitive. It should have the capacity to rule
out patients at increased bleeding risk. The high-risk
patients will require further testing. It should furthermore
be speciﬁc in order to identify patients at low risk that do
not need to be tested. It should have a favorable cost/
efﬁciency ratio. It should increase patient safety and it
should be practicable.
A strategy that addressed these criteria was that
proposed by Koscielny et al, who published two large
studies, each with approximately 5,000 patients. These
studies suggested that performing a bleeding history on all
patients preoperatively allowed for risk stratiﬁcation into
low- and high-risk categories. The high-risk category
comprised 11% of the study population. A retrospective
study suggested that a standardized bleeding history can
identify patients at risk, while a prospective study sug-
gested that risk category allocation-based investigation was
possible (only a minority of approximately 10% were
suggested to have perioperative laboratory testing) and that
treatment based on that risk allocation resulted in peri-
operative transfusion rates that were not statistically
signiﬁcantly different.32,33
Since the turn of the century several bleeding history
questionnaires have been validated and applied. Question-
naires have been proposed by Houry, Koscielny, the
Austrian Society of Anaesthesiology Reanimation and
Intensive Care (OeGARI), and others.33-35 These ques-
tionnaires address primarily the acquired bleeding diathe-
ses, which are highly prevalent. If one suspects a hereditary
bleeding disorder such as von Willebrand syndrome
(vWS) then the MCMDM questionnaire has proven to
be highly sensitive.36 To date, there is accumulating
evidence strongly suggesting that generalized preoperative
screening is costly and not efﬁcient. Despite this evidence,
generalized screening is prevalent. This has led authors to
propose a solution in which bleeding history and addi-
tional risk factor deﬁne risk groups in which no testing,
minimal testing (prothrombin time and platelet count),
standard testing (aPTT, prothrombin time, ﬁbrinogen),
and extensive coagulation testing are proposed.37PREVENTION OF VENOUS
THROMBOEMBOLISM
Perioperative VTE was a relevant problem in view of a
high morbidity and mortality in the 1960s. Fifteen percent
to 40% of major surgery patients, 40%–60% of hip and
knee arthroplasty patients, and 40%–80% of trauma
patients suffer from VTE in the absence of preventive
measures.38 Based on the discovery of risk factors for
perioperative venous thrombosis and the ﬁnding that these
risk factors were cumulative in nature, strategies for the
prevention of VTE were sought. There are generally two
forms of VTE prophylaxis: pharmacologic and mechan-
ical. The effectiveness of oral anticoagulation (VKAs) in
the prevention of DVT after hip surgery was described in
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heparin 3x 5,000 IU subcutaneously with low-molecular-
weight heparin (LMWH) were published in the late
1980s.39 A couple of years later, oral anticoagulation was
proven effective in preventing DVT in major surgery.19
Large randomized controlled trials (RCTs) establishing the
role for VKA in hip replacement surgery were published in
the late 1990s.40,41 Trials with LMWH were performed
only a few years later42 and these were followed by those
for fondaparinux and new direct anticoagulants in
the 2000s.
The duration of prophylaxis for hip and knee replace-
ment initially was 7–10 days. This changed in the early
2000s for high-risk patient populations including total hip
replacement (and later also cancer patients), where an
extended prophylaxis—with an added 3 weeks on top of
the original 7–10 days—was introduced.43
The timing of pharmacologic VTE prophylaxis has
been a major debate. In North America postsurgical start
was propagated for LMWH, while in Europe the presur-
gical start was more frequently followed. For certain
LMWHs this resulted in the adoption of different dosing
schedules. In North America, for example, enoxaparine
was licensed at 30 mg subcutaneously twice per day versus
40 mg subcutaneously once per day in Europe. With the
advent of the novel direct anticoagulants in the late 2000s,
this issue has become obsolete as studies were performed
with a postoperative start of the pharmacological
prophylaxis.
Mechanical measures of VTE prevention have also
been evaluated. Graduated compression stockings and
intermittent pneumatic compression devices have been
shown to be effective as of the mid 1990s and were
included in the relevant American College of Chest
Physicians (ACCP) guidelines thereafter.38 It is of note
that the effect of mechanical and pharmacologic VTE
prevention appears to be additive. This is of importance in
high-risk patients.PERIOPERATIVE THROMBOSIS RISK FACTORS
Perioperative VTE ranging from simple DVT to
pulmonary embolism (PE) and arterial thrombosis
(ATE) were long thought to be a non-preventable side
effects of surgery. The introduction of VTE prophylaxis in
hip arthroplasty patients reduced the proximal DVT rate
from 18%–36% and the fatal PE rate from 0.1%–2.0% to
below 3.4%–4.8% and 0.6%, respectively.38 These num-
bers proved that VTE-related morbidity and mortality
were preventable to a large extent.
The recently published ACCP 2012 perioperative
thromboembolic risk stratiﬁcation of patients discerns three
main categories for VTE prevention: an actutely ill hospi-
talized group (nonsurgical patients), a general and abdom-
inopelvic surgery (non-orthopedic patients) group, and an
orthopedic surgery group44 (Figure 1A and B). Most of the
thrombosis risk factors were identiﬁed over thepast 50 years, along with the better understanding of the
pathophysiologic coagulation mechanisms. They can be
subdivided into modiﬁable and non-modiﬁable risk
factors. Congenital risk factors are non-modiﬁable,
while acquired risk factors can belong to either category
(Table 1).
In 1965, antithrombin deﬁciency was the ﬁrst form of
inherited familial thombophilia identiﬁed.45 During the
1980s, the congenital deﬁciency of each of the natural
anticoagulants proteins C and S, both proteins having
been identiﬁed in the 1970s, were for the ﬁrst time
associated with recurrent thrombotic tendency.46-48 In
1994 the inherited resistance to activated protein C was
attributed to a point mutation in the factor V gene, called
factor V Leiden. This was later shown to be the most
frequent innherited thrombophilia, especially common in
Caucasians.49 Approximately 2 years later, the point
mutation in the prothrombin gene (G20210A), which
was associated with an increased risk of VTE, was
described by the same group.50,51
Antiphospholipid syndrome (APS), an acquired hyper-
coagulable state affecting both the venous and the arterial
vascular bed, was described in full in the 1980s after
various previous reports of antibodies “circulating anti-
coagulants” in patients with systemic lupus erythematosus
and thrombosis and a false positive test for syphilis.52
Currently, the Sydney criteria proposed are used to
diagnose antiphospholipid antibody syndrome.53 Two sets
of criteria need to be fulﬁlled. Any of the following three
criteria need to be met to fulﬁll the clinical criterium:
arterial thromboembolism, VTE, and/or recurrent abor-
tions. In the presence of a positive clinical criterium, then
one of the following laboratory criteria is sufﬁcient for APS
diagnosis: positive lupus anticoagulant, positive anticar-
diolipin antibodies (IgG or IgM), and/or positive anti-β2
glycoprotein antibodies (IgG or IgM). Treatment and
diagnosis have been reviewed recently.54
Increasing age has become an established risk factor for
venous thrombosis. In 1966 Fleming et al reported an
increased prevalence of fatal PE in healthy individuals above
the age of 40. The same study identiﬁed obesity as a
predisposing factor to PE, with 43% of fatal PE cases being
overweight.55 Although obesity was suspected as a risk factor
for VTE as early as the 1920s,56 a consensus for obesity as
an independent risk factor in both men and women was
only recently developed.57 Patients with a body mass index
(BMI) of above 30 have a two times increased relative risk
for VTE. The relative risk rises with increasing BMI above
30.57,58 In both developed and developing countries, where
the prevalence of morbid obesity is continuing to rise,
obesity and advanced age relevantly impact the perioperative
thrombosis management.58
Cancer was initially associated with thrombosis by
Trousseau in 1863.59 Over the last decades the imple-
mentation of new anticancer treatments and prolonged
overall survivor in cancer patients increased the need of
proper perioperative assessment of this population.60
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Figure 1. VTE prophylaxis in acutely ill hospitalized and in orthopedic patients (A) and in non-orthopedic (general and
abdominopelvic surgery) patients (B) as proposed by ACCP 2012. Abbreviations: venous thromboembolism (VTE), high
(hi), surgery (Sx), bleeding risk (BR), yes or high (þ), no or low (), no prophylaxis (No Px), pharmacologic prophlyaxis (Ph
Px), mechanical prophylaxis (Me Px), low molecular weight heparin (LMH), unfractionated heparin (UFH), fondaparinux
(Fon), graduated compression stockings (GCS), intermittent pneumatic compression (IPC), dabigatran (Dab), apixaban
(Api), Rivaroxaban (Riv). This scheme is a simpliﬁcation of the recommendations given by ACCP 2012. The original
documents should be consulted for detailed and accurate information. The ﬁgures given in B represent VTE risk: very low
(o0.5%), low risk (1.5%), high (3%) and very high risk (6%). “Ph Px later” refers to the recommendation of
possibly starting pharmacologic thromboprophylaxis once and if the bleeding risk has diminished.
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ﬁrst time in 1960. Soon after that several concerns
emerged regarding their association with thrombosis
and PE, conﬁrmed by epidemiological data in the
1970s.55,61 Similarly, hormonal replacement therapy
has been associated with a threefold relative risk of
DVT.62The surgical procedure itself represents a transitory
hypercoagulable state, involving both venous and arterial
thrombosis. Major orthopedic surgery is often complicated
by VTE, whereas neurologic and vascular surgical proce-
dures, in patients with atrial ﬁbrillation, are associated
with a greater risk for arterial thromboembolism, including
stroke.63
Table 2. Pharmacological and Blood Compo-
nent Pro-hemostatic Therapies
Fresh whole blood
Red blood cells concentrates
Fresh frozen plasma
Platelet transfusion
Tranexamic acid
Desmopresin
Cryoprecipitate
Table 1. Venous Thromboembolism Risk Factors
Modiﬁable Non-modiﬁable
Surgery Increasing age
Trauma immobility (lower extremity paresis) Previous VTE
Cancer active or occult Factor V Leiden
Cancer therapy Prothrombin mutation G20210A
Venous compression Hereditary antithrombin deﬁciency
Pregnancy and postpartum period (6 weeks) Hereditary protein S deﬁciency
Estrogen-containing oral contraceptives or hormone replacement Hereditary protein C deﬁciency
Selective estrogen receptor modulators
Erythropoiesis-stimulating agents
Acute medical illness
Inﬂammatory bowel disease
Nephrotic syndrome
Paroxysmal nocturnal hemoglobinuria
Obesity
Central venous catheterization
Antiphosphopholid antibody syndrome
S. Valsami and L.M. Asmis84PERIOPERATIVE BRIDGING OF
ANTICOAGULATION AND ANTI-
AGGREGATION
The prevalence of therapeutic anticoagulation in the
general population is approximately 1%. The main indica-
tions are atrial ﬁbrillation, prevention of recurrent VTE,
mechanical heart valves, and APS. Thus the need of
perioperative management of patients on chronic antico-
agulatuion is a relevant challenge. Bridging anticoagulation
can be deﬁned as the administration of short-acting anti-
coagulants consisting of subcutaneous LMWH or intra-
venous unfractioned heparin (UFH), for a 10- to 20-day
period during interruption of VKAs.44 The ﬁrst articles on
bridging were published around the turn of the millen-
nium.64 These and subsequent studies show that thrombotic
risk needs to be counterbalanced against bleeding risk related
to the patient and the surgical procedure. Several approaches
to perioperative management of patients on antithrombotics
have been published since the implementation of anti-
coagulation. In 2012, Siegal et al performed a meta-
analysis of 34 studies.65 The question of whether bridging
is associated with an improved outcome still cannot be
ﬁnally answered. RCTs comparing bridging to no bridging
in patients undergoing elective surgery are ongoing, and
hopefully will answer this relevant question. For perioper-
ative management of antiplatelet therapy, various strategies
have been proposed These rely heavily on expert opinion
and RCT-based data are mostly lacking.Fibrinogen concentrate
Prothrombin complex concentrate
Activated prothrombin complex concentrate
Recombinant factor VIIa
Adapted from Keeling et al54 and Makris et al.86PERIOPERATIVE BLEEDING MANAGEMENT
Despite major advances in the past 50 years and in view
of the associated morbidity and mortality, the management
of perioperative bleeding remains a major challenge. Thissection will very brieﬂy highlight some nonsurgical aspects
of bleeding management. Originally, bleeding management
focused on the restitution of blood components that were
lost. Some current strategies focus more on preventing
blood loss from the beginning. For the management of a
bleeding patient, different blood products and hemostatic
drugs are available (Table 2).
Transfusion medicine started out with whole blood as
the only available product. Plasma as a liquid or a dried
powder was the ﬁrst available isolated blood component
and was used starting from 1942 during World War II.
Whole blood and plasma were initially stored in glass
bottles. Plastic transfusion bags were invented in the 1950s
and progressively replaced the bottles until the 1970s.66
Cryoprecipitates, products rich in von Willebrand factor
and FVIII, were introduced in 1965. Plasma fractionation
methods permitted the production of factor concentrates,
50 Years of perioperative thrombosis and hemostasis management 85including non-activated concentrates (prothrombin com-
plex concentrates, ﬁbrinogen, FXIII, FVIII, and FIX) and
activated concentrates (FVIII inhibitor bypassing agent).67
In 1969, Murphy and Gardner demonstrated the feasi-
bility of storing platelets at room temperature, revolutio-
nizing platelet transfusion therapy.68 Most recently,
recombinant coagulation factor preparations both non-
activated (FVIII, FIX, FXIII) and activated (recombinant
human FVIIa) have become available.
The transfusion of blood products necessitates a risk
beneﬁt evaluation. History has shown that there are relevant
risks associated with the transfusion of both cellular and cell-
free blood products. Although hepatitis B virus (HBV)
infection, called ”serum hepatitis” at the time, was recognized
as a complication of blood transfusion in survivors of World
War II, it took nearly three decades to identify HBV the
virus and develop HbSAg testing.69 In the early 1980s, there
was a tragic epidemic of HBV, HCV, and human immu-
nodeﬁciency virus (HIV) among hemophilia patients who
had received contaminated concentrates prepared from large
plasma pools.70 Donor blood testing for HIV started in 1985
and for HCV in the early 1990s.71,72 Efforts to implement
pathogen-reduction technologies in blood, initially plasma
and derivates, started in the 1980s and are still ongoing.73
Currently, although transfusion of blood components is
safer than ever, it remains hazardous. The transmission of
known and emerging pathogens as well as non-infectious
complications are unsolved problems.73,74 During the last
decade several studies suggested that transfusion of blood
components was associated with adverse clinical outcome,
particularly increased morbidity and mortality. In a large
meta-analysis published in 2008 regarding erythrocyte
blood (RBC) transfusions in the critically ill, it has been
shown that in 42 of the 45 studies, RBC transfusion was
associated with unfavorable outcome of the patients, in two
the transfusion beneﬁts were equal to the risks, and only in
one transfusion beneﬁts were superior to the risks.75
Similarly RBC transfusions were associated with increasing
mortality in trauma patients, burn victims, and liver trans-
plantation patients, and in the treatment of acute coronary
syndrome.75-77 A meta-analysis found that restrictive trans-
fusion practices using thresholds of 7–8 g/dL versus higher
thresholds are associated with fewer RBC units being
transfused without evidence of adverse outcome on mortality,
morbidity, functional recovery, and length of hospital stay. In
addition, transfusion of RBCs, fresh frozen plasma (FFP),
and mainly platelets results in a higher risk for postoperative
and nosocomial infections.73,75 FFP transfusion has been
associated with increased morbidity in different patient
populations and with increased mortality in non-trauma
patients.78,79 To date there is ongoing debate of how to
manage the bleeding patients. There are approaches that
propose transfusion strategies with high plasma to RBC
ratios.80 Other approaches to perioperative bleeding manage-
ment, for which relevant RCTs have been published recently,
are early treatment with ﬁbrinolysis inhibitors (CRASH-2
study in trauma), the targeted approach using factorconcentrates and point-of-care testing (thromboelastogra-
phy/metry), and the patient blood management con-
cepts.81-85SUMMARY AND PROSPECTS
Perioperative thrombosis and hemostasis management
has evolved considerably over the past 50 years. The
individual patient is at the center and optimal patient
outcome should be its goal. Key challenges towards the
achievement of that goal include the generation, validation,
and implementation of evidence-based practices that inte-
grate outcome-based research, individual risk-beneﬁt evalu-
ations, and public interests (cost of healthcare). As this ﬁeld
of medical expertise is growing increasingly complex,
frequent interaction among and active communication
between the patients, nursing staff, surgeons, anesthesiolo-
gists, intensive care physicians, hematologists, and other
involved physicians is essential for continued success.
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